A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food and Ketoconazole on the Pharmacokinetics of IPI-145 When Administered to Healthy Adult Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food and Ketoconazole on the Pharmacokinetics of IPI-145 When Administered to Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Duvelisib (Primary) ; Ketoconazole
  • Indications Allergic asthma; Haematological malignancies; Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2012 Results will be presented at the Annual Meeting of the American College of Rheumatology (ACR) in November 2012, according to an Infinity Pharmaceuticals media release.
    • 07 Aug 2012 Additional results are expected to be presented at a medical meeting in the second half of 2012.
    • 27 Jun 2012 Results will be presented at a conference in the second half of 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top